# Tenecteplase for Intravenous Stroke Thrombolysis in Recent DOAC Users

Study · id `cardio:ct-nct07092709` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07092709](<https://clinicaltrials.gov/study/NCT07092709>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07092709

Browse, organ or system: Brain  
Browse, condition area: Stroke  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 912 participants.

## Technical summary

Registry record NCT07092709. Randomized; quadruple masking; primary purpose treatment. Start 2025-08-14 (actual); primary completion 2028-09-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 912 participants (planned count; ClinicalTrials.gov record NCT07092709, source copy `cardio:ctgov-nct07092709-2025-12-16`, retrieved 2026-10-26)
- Started: 2025-08-14 (actual) (ClinicalTrials.gov record NCT07092709, source copy `cardio:ctgov-nct07092709-2025-12-16`, retrieved 2026-10-26)
- Primary completion: 2028-09-01 (anticipated) (ClinicalTrials.gov record NCT07092709, source copy `cardio:ctgov-nct07092709-2025-12-16`, retrieved 2026-10-26)
- Completion: 2028-12-31 (anticipated) (ClinicalTrials.gov record NCT07092709, source copy `cardio:ctgov-nct07092709-2025-12-16`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT07092709, source copy `cardio:ctgov-nct07092709-2025-12-16`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07092709-2025-12-16`, retrieved 2026-10-26)

## The registry's words

- Brief title: Tenecteplase for Intravenous Stroke Thrombolysis in Recent DOAC Users
- Acronym: PEARL-DOAC
- Condition: Acute Ischemic Stroke
- Intervention (Drug): Tenecteplase (TNK) (0.25 mg/kg, to maximum of 25mg)
- Intervention (Drug): Placebo
- Lead sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Ischemic stroke (`cardio:ischemic-stroke`)
- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry intervention name matches this record once doses, forms and salt words are removed: Tenecteplase (`cardio:tenecteplase`)
- Registry intervention is a member of this class by a sourced record link: Fibrinolytic (clot-dissolving) drugs (`cardio:fibrinolytic-clot-dissolving-drugs`)
- Registry lists this organization as the lead sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (`cardio:org-sun-yat-sen-memorial-hospital-of-sun-yat-sen-university`)

## Provenance

Content hash: ef49b1dfb5cc1148b600aee7da1a588a613549ff321446489c14d3fe477c2ad7
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
